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Background: Blood products are commonly transfused for patients with non-variceal upper 
gastrointestinal bleeding (NVUGIB). While concerns exist about further bleeding and mortality in 
subsets of patients receiving red blood cells (RBCs) transfusion, the impact of non-RBC blood products 
has not previously been systematically investigated. The aim of the study was to investigate the 
associations between blood products transfusion, further bleeding and mortality after acute NVUGIB.  
Study Design and Methods: Retrospective cohort study examining further bleeding, 30-day and one-
year mortality in adult patients who underwent gastroscopy for suspected acute NVUGIB between 
2008 and 2010 in three tertiary hospitals in Western Australia. Survival analysis was performed. 
Results: 2,228 adults (63% male) with 2,360 hospital admissions for NVUGIB that met the inclusion 
criteria. Median age at presentation was 70 years (range 19 to 99 years). 30 day mortality was 4.9% 
and one-year mortality 13.9%.  Transfusion of four or more units of RBCs was associated with greater 
than ten times the odds of further bleeding in patients with hemoglobin >90g/L (OR 11.9; 95% CI 3.1-
45.7; p=<0.001), but was not associated with mortality.  Administration of five or more units of fresh 
frozen plasma (FFP) was associated with increased 30-day (HR 2.8; 95% CI 1.3-5.9; p=0.008) and one 
year mortality (HR 2.6; 95% CI 1.3-5.0; p=0.005) after adjusting for coagulopathy, comorbidity, Rockall 
score and other covariates.   
Conclusion: In this large, multicentre study of NVUGIB, RBC transfusion was associated with further 
bleeding but not mortality, while FFP transfusion was associated with increased mortality in a subset 
of patients. 
Keywords: non-variceal upper gastrointestinal bleeding; red blood cell transfusion, fresh frozen 
plasma, survival analysis, mortality, gastrointestinal bleeding 
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Introduction                   
Acute non-variceal upper gastrointestinal bleeding (NVUGIB) is a common medical emergency 
associated with significant morbidity, mortality, and substantial health care costs. Despite recent 
advancements in endoscopic hemostasis, the 30-day mortality from upper gastrointestinal bleeding 
(UGIB) remains 5% to 14% 1-3. Males and the elderly appear to be most vulnerable to UGIB 3. 
Transfusion practice for acute UGIB is largely empiric 4, however with declining blood donations 
relative to demand, better evidence for blood transfusion is needed 5.  Gastrointestinal blood loss, 
primarily UGIB, accounts for 21% of red blood cell (RBC) transfused in Western Australia (WA) 
{personal communication, WA Patient Blood Management Program}. Whilst transfusion may be life-
saving in massive UGIB, there is little evidence to support its use in less severe bleeding.  An 
observational study from the UK reported that 19% of patients who received an early RBC transfusion 
had an initial hemoglobin (Hb) of >80g⁄L, and satisfactory hemodynamic status 6.  
A recent randomized controlled trial concluded that there was a reduction in mortality in patients with 
UGIB under a restrictive RBC transfusion strategy compared with a more liberal transfusion strategy 
7. Large observational studies from the UK and Canada concluded that RBC transfusion for UGIB was 
associated with increased rates of rebleeding but not mortality 6, 8. By contrast, another UK study 
reported increased 30-day and 2-year mortality after RBC transfusion 9.    
Although RBC transfusion has been associated with increased short-term morbidity and mortality, 
little is known about outcomes following administration of fresh frozen plasma (FFP) or platelets in 
NVUGIB. Even in critically ill patients, current guidelines for FFP and platelet transfusion are weak 10, 
11.  Consequently, we aimed to examine for associations between blood products transfusion (RBC, 
FFP and platelets), further bleeding and mortality at 30 days and 1 year after acute NVUGIB.  
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Materials and Methods 
 
Study design 
This was a retrospective cohort study of all patients who underwent gastroscopy for an acute NVUGIB 
event at three WA tertiary hospitals that have on-call endoscopic services, over a three year period 
(2008-2010).  Institutional ethics review board approval was granted by the human research ethics 
committees of the WA Department of Health, Curtin University, Fremantle Hospital, Royal Perth 
Hospital and Sir Charles Gairdner Hospital.  
Cohort selection 
Study participants were identified from electronic medical records of all gastroscopy procedures 
carried out in the three participating hospitals during the study accrual period 1 January 2008 to 31 
December 2010.  Inclusion criteria were age 18 years and over at presentation with hematemesis 
and/or melena. Day case and outpatient procedures and patients with portal hypertensive 
gastropathy or varices were excluded.  Patients were followed-up for 29-65 months, until the study 
censor date of 31 May 2013. 
Data collection 
A medical chart review was conducted for eligible acute NVUGIB admissions by dedicated research 
nurses. Detailed admission and procedural data, including presenting symptoms and signs, laboratory 
results, medications, comorbidity, time from bleed to gastroscopy, endoscopic findings and treatment 
and any requirements for surgery or radiological intervention were collected.  The volumes and types 
of transfused blood products, infused colloid or crystalloid products used prior to first gastroscopy 
were also collected.  
Further data on patients were obtained from an extraction of person-level linked hospital morbidity 
records, patient blood management and death registration records from the Data Linkage Branch of 
the WA Department of Health.  These included patient socio-demographic variables, previous history 
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of UGIB and comorbidities, total blood product use per admission and dates of death.  All analyses 
were performed on de-identified data. 
Variable definitions 
Acute UGIB admission-specific variables recorded included the in- or out-of hospital location at the 
time of bleeding, transfer from a peripheral hospital, presenting symptoms and signs, cardio-
respiratory or neurological comorbidity and sequelae of the bleeding episode. Additional comorbidity 
information was defined using International Classification of Diseases (ICD)-10-AM 12 codes to create 
Elixhauser binary indicators from conditions recorded during in-patient hospitals stays within the year 
prior to and including the acute UGIB admission 13.  
A post-endoscopy Rockall risk score was calculated for each acute UGIB admission14.  The Rockall score 
was designed to predict the risk of mortality in UGIB and takes into account patient age, comorbidity, 
diagnosis, shock and evidence of bleeding. In cases where systolic blood pressure or heart rate at 
admission was missing the patient was given a zero score in the shock domain.  The comorbid domain 
of the Rockall risk score was assigned using specific comorbid conditions present at time of admission 
(ICD-10-AM codes: I50 I20-I25 C77-C79 K72 K704 N17-N19).  Patients with a one-year history of 
congestive heart failure, peripheral vascular disease, metastatic solid tumours or weight loss were also 
assigned a Rockall comorbidity score of two as these conditions were found empirically to be 
associated with increased odds of mortality after adjusting for age and all comorbidity.  
The Child-Pugh Class, used as measure of prognosis in chronic liver disease, was calculated for 
admissions with documented liver disease. Admissions where data on bilirubin and serum albumin 
levels at admission were missing were classified as unknown Child-Pugh score.  
Coagulopathy at time of admission was defined as moderate with an international normalised ratio 
(INR) >1.2 and/or platelet count <150,000/mm3 and severe with INR>1.5 and/or platelet count 
<=50,000/mm3.  The lowest documented haemoglobin (Hb) associated with the NVUGIB episode prior 
to the first gastroscopy was categorised as <70g/L, 70-90 g/L and >90 g/L. Lowest Hb for the admission 
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was similarly categorised. These categories were chosen to match that used as a trigger for transfusion 
in the recent randomised controlled trial7.  Renal and liver biochemistry and fibrinogen values were 
recorded. The volumes of colloid and crystalloid fluid resuscitation, RBC, FFP, cryoprecipitate and 
platelets transfused prior to first gastroscopy and over the complete admission were recorded. An 
early RBC, FFP or platelet transfusion was defined as being prior to first gastroscopy. 
A detailed record of medications at admission, including anticoagulant and antiplatelet medication, 
was classified into 41 categories loosely based on the Australian Pharmaceutical Benefits Scheme drug 
classes.  Treatment with Vitamin K, Prothrombinex, proton-pump inhibitors, (PPI), Octreotide or 
Terlipressin prior to gastroscopy, gastroscopy-related information including duration of procedure, 
type and site of the bleeding lesion, Forrest criteria 15, endoscopic, radiologic or surgical procedures 
undertaken to arrest the bleeding, and post-gastroscopy morbidities were recorded. Calendar year of 
admission and individual hospital was also available. 
Blood product preparation  
RBC and all blood components used in the study hospitals were obtained from the Australian Red 
Cross Blood Service (ARCBS) in Western Australia. 
RBCs for transfusion were obtained by removing most of the plasma after centrifuging whole blood 
collected into citrate phosphate dextrose anticoagulant. The shelf life (time available for use) was up 
to 42 days and they were stored at 2-6 degrees centigrade. All RBCs were leucodepleted. When 
required, RBCs were released from ARCBS at 7-8 days post collection. The average age of red cells 
transfused in Western Australia was 24 days. 
Apheresis or single donor platelets in Western Australia accounted for 75% of supply. The remaining 
adult doses of donor platelets were derived from pooled buffy coats derived from four ABO identical 
donors and resuspended in a nutrient additive solution to produce a pooled platelet component. Both 
apheresis and pooled platelets were leucodepleted during or soon after collection and they are 
also irradiated before release from the Blood Service16. 
   
8 
 
FFP was derived from either a collection of whole blood or apheresis plasma.  FFP was not 
leucodepleted. To be suitable for clinical purposes, whole blood plasma was separated from the whole 
blood unit within 6 hours of collection. The freezing process commenced within 18 hours of 
collection. All FFP was frozen to a core temperature below -30ºC within 1 hour of commencement of 
the freezing process. 
FFP in Australia is not yet pathogen inactivated by photo inactivation or solvent detergent treatment 
but there is a strong framework to ensure safety with regards to transfusion transmitted infections 
evident in globally low ARCBS residual rates of transmission as judged by mandatory testing.        
A unit of FFP contains all coagulation factors including the labile plasma coagulation Factors VIII and 
V. An adult dose contained approximately 200 IU of Factor VIII. FFP can be stored for 12 months at -
25ºC or below16. 
Outcome measures 
The principal outcome measures were early further bleeding, 30-day and conditional one-year 
mortality after the last NVUGIB hospitalisation.  Early further bleeding was defined by further 
hematemesis or passage of fresh melaena and a) a gastroscopy-confirmed lesion that was bleeding 
or showed signs of recent bleeding occurring after the initial gastroscopy but during the same 
hospitalisation, b) a post-gastroscopy radiological hemostatic intervention, c) evidence of surgical 
repair of an upper gastrointestinal lesion in the same admission and at a later date than first 
gastroscopy, or d) readmission to hospital within 30 days of discharge with another acute NVUGIB. 
One year mortality outcomes were conditional upon surviving the first 30 days post first gastroscopy. 
Statistical methods 
Logistic regression models were used to investigate factors associated with odds of early further 
bleeding.   The lack of independence that arose from some patients having had multiple acute NVUGIB 
admissions was accounted for by using a clustered sandwich variance estimator. Models were fitted 
using a purposeful stepwise approach and final models only included variables that were significant 
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at the 0.05 level (parsimonious approach) except for forced inclusion of variables indicating units of 
RBCs, Platelets and FFP. Plausible interactions were investigated where appropriate.  Chi-square tests 
were used to assess equality of proportions and nonparametric k-sample equality of medians test 
used to asses medians.  The level of collinearity between variables included in regression models were 
assessed using the conditioning of the matrix procedure available in Stata. 
Survival analysis was performed from the time of first gastroscopy in the last NVUGIB admission for 
each patient until date of death or census times (30 days or one-year).  Data were incorporated into 
the counting process format so that the timing of multiple gastroscopies was taken into account. Cox 
models were used to identify factors associated with mortality outcomes using a parsimonious 
approach except for forced inclusion of blood product variables. Schoenfeld residuals were used to 
test for violation of the proportional hazards assumption.  
 
Results 
We identified 2,238 patients with 2,371 acute NVUGIB hospitalisations that met the inclusion criteria 
(Figure 1).  Eleven admissions were missing an admission Hb result and these were excluding leaving 
2360 acute NVUGIB hospitalisations for 2228 patients. Most patients (n=2,122; 95%) experienced a 
single NVUGIB admission.  The cohort was predominantly male (63%), with median age of 70 years 
(range 19 to 99 years).  Approximately one-quarter (n=650; 28%) were transferred from a peripheral 
general hospital where emergency endoscopy was not available.  Seventeen percent (n=408) of acute 
UGI bleeds occurred in patients who were already hospitalised for other reasons.  At admission, 24% 
(n=568) of patients were not taking PPI, anti-platelet, anti-coagulant or H2 antagonist medications. 
More than half of the patients presented with Hb <90g/L and these patients tended towards more 
coagulopathy, higher Rockall scores, active bleeding, female gender and older age. (Table 1).  Overall 
mortality was 4.9% (95%CI: 4.0-5.8), 13.8% (95%CI: 12.5-15.3) and 19.6% (95%CI: 18.0-21.3) at 30 
days, one year and two years respectively. 
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Volume resuscitation and blood product use prior to first gastroscopy 
Early volume resuscitation prior to first gastroscopy occurred in 97% (n=2,280) admissions, including 
57% with RBC, 13% with FFP and 3% with platelet transfusion (Table 1). Overall, 63% (n=1,482) of 
admissions involved RBC transfusion.   Crystalloid was delivered prior to first gastroscopy in most 
admissions (n=2197; 93%) with over 55% receiving 2000ml or more (n=1,310).  Colloid was used pre-
gastroscopy in 11% of NVUGIB admission (n = 268) and cryoprecipitate in 18 (0.8%) admissions. 
Gastroscopy findings 
Most UGI lesions showed no endoscopic features of a recent bleed (Table 1).  Fourteen percent of 
gastroscopies identified active or oozing bleeding and the remaining 20% had stigmata of recent 
haemorrhage ranging from flat, pigmented lesions (n=61) to visible blood vessels (n=192).  Over 46% 
(n=1,098) of acute NVUGIB were associated with ulcer disease. Other findings included esophagitis, 
gastritis or duodenitis in 23% (n=538), Mallory-Weiss tears 5.8% (n=136), angiodysplasia 4.6% (n=109), 
UGI cancers 2.1% (n=49), Dieulafoy lesions 1.4% (n=34) and Cameron's ulcers 0.5% (n=12). Bleeding 
from surgical anastomotic sites, polyps and unspecified lesions were also rarely noted. In 1.1% (n=26) 
of admissions, bleeding could not be attributed to a site or lesion, despite fresh blood being observed.   
Early further bleeding 
Early further bleeding requiring treatment was observed in 116 (4.9%) patients.  Multivariable logistic 
regression was used to identify patient characteristics and clinical management practices that were 
associated with odds of further bleeding (Table 2).  A significant interaction between Hb and RBC units 
transfused was present in this model. Patients presenting with low Hb (≤ 70g/L) were more likely to 
experience further bleeding compared to those with Hb >90g/L when no early RBC units were 
transfused OR 7.2; 95%CI 2.0-25.9).  However, the effect of RBCs on further bleeding varied depending 
on the admitting Hb level.  For patients admitted with a Hb <=90 g/L there was no association between 
the number of RBC units transfused pre-gastroscopy and the odds of early further bleeding.  This was 
not the case for patients admitted with a Hb>90 g/L where there was a linear association of increasing 
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odds of early further bleeding with increasing units of pre-gastroscopy transfused.     Duodenal ulcers, 
perforated ulcers, upper GI cancer, Dieulafoy lesions, an in-hospital UGIB, and UGI lesions with 
stigmata of high risk of rebleed or necessitating endoscopic therapy were more likely to experience 
further bleeding.  Coagulopathy or being on warfarin at presentation was not associated with further 
bleeding in this cohort. 
30-day mortality  
One hundred and eight (4.9%) patients died within 30 days of first gastroscopy for an acute NVUGIB, 
with most deaths (n=74) occurring in hospital.  UGI conditions, including cancer, were the cause or 
contributory cause of death noted on the death certificate in 35% (n=38) of deaths within 30 days. An 
additional 12% (n=13) were attributed to other digestive system disorders; 21% (n=23) non-upper GI 
cancer; and 15% (n=17) to disorders of the circulatory system.   
In a multivariate Cox survival model that included multiple comorbidity indicators and coagulopathy 
status, a significantly  increased 30-day mortality was observed for patients transfused with five or 
more units of FFP with some evidence of an increasing linear association observed (Table 3).   Further 
investigation showed that 11/89 (12.4%) patients who received 5+ units of FFP had a complication 
following transfusion/infusion/injection (ICD 10 T80 code) or post procedural respiratory disorder (ICD 
10 J95 code) recorded for the hospital admission compared to 6/313 (1.9%) patients who received 
between 1 and 4 units of FFP. 
The association of platelet transfusion with 30-day mortality was observed to be modified by serum 
albumin levels at admission.  For patients with a serum albumin < 35 at admission, platelet transfusion 
was not associated with increased rate of dying.  However, for patients admitted with a serum albumin 
>=35, the rate of dying was 7 times faster for those who received three or more units of platelets 
during the admission.  No association between the volume of RBC transfused and 30 day mortality 
was observed in this cohort (Table 3).   The survival models also estimated increased 30-day mortality 
was associated with admissions requiring longer duration gastroscopy, gastroscopy performed in ICU 
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and patients who experienced post gastroscopy cardiac complication, increasing Rockall score, 
increasing age, moderate coagulopathy, metastatic cancer, liver disease and use of anti-psychotic 
medication at admission.  Hb at admission or lowest recorded Hb during the admission was not 
associated with 30-day survival outcomes. 
One-year conditional survival outcomes  
The association of FFP, RBC and platelets with longer term survival outcomes was investigated. A 
further 200 deaths occurred after 30 days but within one year of the date of first gastroscopy in the 
last NVUGIB admission.  Upper GI conditions, including cancers, accounted for 14% of deaths, while 
non-UGI cancers (35%) and vascular disease (22%) accounted for most other deaths.   
Patients transfused with five or more units of FFP during their last UGIB admission had almost 2.5 
times the rate of dying during the following year, provided that they survived the first 30 days and 
after accounting for coagulopathy related variables (INR, platelets and warfarin).  Moderate and 
severe coagulopathy at time of admission were associated with poorer one year survival outcomes 
but only in patients not on warfarin at admission.  Coagulopathy in the presence of warfarin was not 
associated with one’s survival. There was no evidence that RBC transfusion, platelet transfusion was 
associated with long-term conditional mortality (Table 4).   
Increasing Rockall score, increasing age, increasing length of stay in hospital, liver disease, malignancy, 
taking anti-anaemic, diuretics or antibiotics at admission and finding Mallory-Weis tears at 




In this large multicenter study of acute NVUGIB, early RBC transfusion was associated with increased 
odds of further bleeding while increased mortality was observed in a subset of patients transfused 
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with multiple units of FFP.   The strengths of this study were the large sample size from three tertiary 
referral hospitals and complete follow-up resulting from linkage to multiple registries including 
hospital admissions and death registry.  Limitations include the observational design which means that 
residual confounding from unmeasured or unknown confounders could not be accounted for which 
limits the ability to draw causal inference of the observed association.  
Our finding of increased further bleeding with early RBC transfusion partly supports those of other 
observational studies 6, 8 and randomized trials7, 17, however we observed that the risk was limited to 
patients who presented with Hb >90g/L. There are a number of mechanisms postulated to explain the 
increased mortality and morbidity with a liberal transfusion strategy. These include abnormalities in 
coagulation, clot rupture when hypotension is eliminated by repletion of blood volume, 
immunomodulation and changes in storage lesion18. Unique to our study was the finding of increased 
odds of further bleeding with increasing RBC administration in patients with Hb >90g/L when 
compared to otherwise identical patients who did not receive RBCs. We found no association between 
further bleeding and increasing RBC administration in patients presenting with Hb<=90g/L.  Whilst our 
observations are broadly consistent with the observations of Villanueva et al7, they add to the original 
Spanish study by demonstrating a Hb level above which further bleeding is much more likely to occur 
if RBCs are administered.  
In the local Australian setting, RBC transfusion to Hb >90g/L was at the discretion of various physicians 
and probably reflects the previous recommendations to transfuse to Hb ≥100g/L19, 20.   More recent 
guidelines published after this study period state that RBC transfusion should not be dependent on 
Hb concentration alone, but a whole patient assessment that includes decompensated liver disease, 
age and comorbidity21. The observed further bleeding rate of 4.9% was less than that reported in other 
observational studies6, 8, although this in part may be due to differences in defining a further bleed. 
Our study needed confirmation of further bleed with endoscopy.   However, it could also reflect a shift 
in blood transfusion attitudes and practice following the local introduction of evidence-based patient 
blood management in one of the tertiary hospital included in this study22.  
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The 30-day mortality rate of 5% reported here is consistent with studies from Europe23, Canada24and 
Asia25  while the 19.5% two-year mortality rate is a little less than the 26% reported in the UK9.   RBC 
transfusion was not associated with 30-day or conditional 1-year mortality in our study, similar to that 
reported by two other observational studies6, 8.   This contrasts with a randomised trial that found 
increased 45-day mortality in patients assigned to a liberal transfusion strategy (Hb threshold 90g/L) 
compared to patients allocated to a more restrictive transfusion strategy (Hb threshold 70g/L)7.  The 
trial selection criteria included acute variceal bleeding but excluded patients at low risk for mortality, 
with massive exsanguinating bleeding, symptomatic coronary, cerebral or peripheral vascular disease, 
transfusion within 90 days, recent trauma or surgery, and lower GI bleeding. By contrast, our study 
included all severities of NVUGIB examined with gastroscopy though we were not privy to specific 
factors triggering the clinical decision to administer blood products. 
The use of five or more units of FFP was associated with poorer 30-day and one-year survival outcomes 
with more post procedural respiratory disorders and transfusion related events being recorded. The 
value of FFP on survival outcomes has been questioned in trauma, intensive care and cardiac surgery 
patients26-28.  Reported adverse effects of transfusion include transfusion-associated lung injury and 
circulatory overload, with the risk of acute lung injury being higher in patients who received FFP and 
platelets than in those who received only RBCs29.  The association of FFP with mortality in our study 
was independent of RBC transfusion and was dose-dependent.   
Recent Australian guidelines recommend that FFP transfusion in the setting of major RBC transfusion 
be guided by both the coagulation profile and clinical scenario, with an INR of >1.5 likely reflecting a 
coagulopathy requiring correction by FFP and /or other coagulation factors 30 although in one study 
involving   trauma patients requiring a non-massive transfusion  ( <10 units packed RBCs within 12 
hours after admission) the administration of more than 6 units of FFP  compared with no transfusion 
was associated with a 12-fold increase in the rate of ARDS and 6-fold increase in multiorgan 
dysfunction syndrome with no improvement in survival31.  
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The association of FFP with increased mortality remained even after one year which is more difficult 
to reconcile biologically.  However, the observational nature of this study means that unmeasured and 
unknown variables related to mortality could be confounding the role of FFP and one year mortality. 
While poorer longer term outcomes with FFP use have been reported in a trauma setting32 in this 
study it is possible that unmeasured reasons that triggered the use of FFP in these patients rather than 
the FFP per se is playing a role. Elucidation of the factors involved is beyond the scope of the current 
study and requires further evaluation. 
There has been concern regarding adverse patient outcomes and the longer storage time of red cells 
transfused especially in the critical care setting.  The average age of RBCs received by patients in our 
study was 24 days. This topic has been reviewed elsewhere33, 34 , but to date there have been no 
consistent adverse findings determined from the transfusion of older stored RBCs to alter clinical 
practice.  
The stringent quality control in the collection, preparation and administration of RBCs and other blood 
products in Western Australia mitigates against reduced product quality as a contributor to the 
adverse outcomes16,  
In conclusion, early RBC transfusion was associated with increased further bleeding in NVUGIB 
patients presenting with Hb >90g/L.  Massive transfusion with FFP, but not RBC transfusion, was 
associated with increased mortality outcomes for patients.  While a causal relationship between FFP 
use and mortality cannot be drawn, judicious use of FFP guided by the coagulation status of the patient 
is advisable. Randomized clinical trials are necessary to examine the benefit versus risk of FFP 
transfusion in NVUGIB patients. 
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Table 1. Patient characteristics and findings during NVUGIB admissions (n=2360) 
 All 
n=2360 
 Haemoglobin at admission (g/L)  
  <=70 (n=417)  >70-90 (n=833)  >90 
(n=1010) 
p-value 
 No. %  No. %  No. %  No. %  
Sex             
Male 1,505 63.9  273 60.3  514 60.7  718 67.9 
0.001 
Female 852 36.1  180 39.7  333 39.3  339 32.1 
             
Median Age (IQR)  70 56-81  73 59-82  73 62-82  66 53-78 <0.001 
             
Coagulopathy              
None 1325 56.1  185 44.4  428 51.4  712 64.4 
<0.001 
INR>1.2 or Platelets<=150‡ 659 27.9  133 31.9  249 29.9  277 24.8 
INR>1.5 or Platelets<=50‡ 376 15.9  99 23.7  156 18.7  121 10.8  
             
RBC pre-gastroscopy             
None 1055 44.7  34 8.2  149 17.9  872 80.1 
<0.001 
1 unit 212 9.0  24 5.8  106 12.7  82 7.3 
2 units 489 20.7  66 15.8  322 38.7  101 7.8 
3 units 259 11.0  105 25.2  128 15.4  26 2.2 
4 units 201 8.5  116 27.8  66 7.9  19 1.8 
5+ units 144 6.1  72 17.3  62 7.4  10 0.8 
             
FFP pre-gastroscopy             
None 2051 86.9  319 76.5  704 84.5  1028 93.0 
<0.001 
1 unit 83 3.5  30 7.2  37 4.4  16 1.2 
2 units 162 6.9  50 12.0  62 7.4  50 4.4 
3 units 14 0.6  4 1.0  4 0.5  6 0.5 
4 units 33 1.4  7 1.7  19 2.3  7 0.6 
5+ units 17 0.7  7 1.7  7 0.8  3 0.3 
             
Platelets pre-gastroscopy             
None 2280 96.6  385 92.3  799 95.9  1096 98.8 
<0.001 
1 unit 58 2.5  20 4.8  29 3.5  9 0.8 
2 units 16 0.7  9 2.2  3 0.4  4 0.3 
3+ units 6 0.3  3 0.7  2 0.2  1 0.1 
             
Gastroscopy findings             
UGI pathology, no blood 1556 65.9  230 55.2  508 61.0  818 74.2 
<0.001 Stigmata of RH 476 20.2  94 22.5  195 23.4  187 16.7 
Active bleeding 328 13.9  93 22.3  130 15.6  105 9.1 
             
Rockall score             
<3 946 40.1  107 25.7  255 30.6  584 53.6 
<0.001 
3-4 622 26.4  106 25.4  223 26.8  293 26.2 
5-7 630 26.7  159 38.1  281 33.7  190 16.6 
>=8 162 6.9  45 10.8  74 8.9  43 3.6 






           
 





 Haemoglobin at admission (g/L)  
  <=70 (n=417)  >70-90 (n=833)  >90 
(n=1010) 
p-value 
 No. %  No. %  No. %  No. %  
 
 
Total RBC in admission             
None 878 37.2  16 3.8  66 7.9  796 73.7 
<0.001 
1 unit 120 5.1  4 1.0  45 5.4  71 6.2 
2 units 456 19.3  27 6.5  302 36.3  127 10.4 
3 units 208 8.8  69 16.5  107 12.8  32 2.5 
4 units 262 11.1  106 25.4  119 14.3  37 3.1 
5 units 125 5.3  50 12.0  59 7.1  16 1.2 
6+ units 311 13.2  145 34.8  135 16.2  31 2.8 
             
Total FFP in admission             
None 1958 83.0  286 68.6  662 79.5  1010 91.3 
<0.001 
1 unit 68 2.9  22 5.3  28 3.4  18 1.5 
2 units 167 7.1  45 10.8  76 9.1  46 4.2 
3 units 21 0.9  11 2.6  7 0.8  3 0.2 
4 units 57 2.4  15 3.6  29 3.5  13 1.0 
5+ units 89 3.8  38 9.1  31 3.7  20 1.8 
             
Platelets in admission             
None 2171 92.0  347 83.2  757 90.9  1067 96.3 
<0.001 
1 unit 106 4.5  32 7.7  47 5.6  27 2.4 
2 units 46 1.9  20 4.8  16 1.9  10 0.8 
3+ units 37 1.6  18 4.3  13 1.6  6 0.6 
RH= recent haemorrhage, FFP = fresh frozen plasma, RBC = Red Blood Cells, ‡Platelets = x 1000 /mm3.  
IQR = Inter-quartile range 
  
   
23 
 
Table 2.  Factors associated with odds of early further bleeding following an UGIB admission as 
estimated by a logistic regression model with robust variance estimators (n=2370 admissions) 
 OR 95%CI p-value 
Hb at admission <70g/L†     
No pre-gastroscopy RBC 1.0 - - 
1 unit RBC  0.23 0.03 - 2.16 0.201 
2 units RBC 0.60 0.15 - 2.34 0.462 
3 units RBC  0.75 0.20 - 2.81 0.670 
4 units RBC 0.63 0.17 - 2.31 0.482 
5+units RBC  0.57 0.15 - 2.21 0.418 
    
Hb at admission >=70g/L and <=90g/L†    
No pre-gastroscopy RBC 1.0 - - 
1 unit RBC  0.59 0.20 - 1.71 0.329 
2 units RBC 0.65 0.29 - 1.44 0.289 
3 units RBC  0.86 0.33 - 2.24 0.754 
4 units RBC 0.88 0.33 - 2.32 0.796 
5+units RBC  0.60 0.18 - 1.99 0.403 
    
Hb at admission >90g/L†    
No pre-gastroscopy RBC 1.0 - - 
1 unit RBC  1.59 0.31 - 8.17 0.580 
2 units RBC 1.15 0.23 - 5.74 0.864 
3 units RBC  4.15 0.70 - 24.47 0.116 
4 units RBC 11.89 3.09 - 45.74 <0.001 
5+units RBC  15.85 2.36 - 106.67 0.004 
    
Coagulopathy at admission    
None 1.0 - - 
INR>1.2 or Platelets<=150,000/mm3 0.86 0.51 - 1.43 0.556 
INR>1.5 or Platelets<=50,000/mm3 1.51 0.74 - 3.06 0.256 
    
On warfarin at admission (yes vs no) (n=264) 0.93 0.41 - 2.10 0.857 
In hospital bleed (yes vs no)   (n=408) 2.15 1.34 - 3.44 0.002 
Endoscopic therapy required (yes vs no)  (n=665) 2.44 1.56 - 3.83 <0.001 
Active bleed / high risk stigmata (yes vs no)  (n=221) 1.85 1.10 - 3.14 0.021 
    
Findings on gastroscopy  (yes vs no)    
Dieulafoy lesion  (n=37) 2.87 1.14 - 7.18 0.025 
Duodenal ulcer (n=563) 2.67 1.72 - 4.14 <0.001 
Perforated ulcer (n=42) 4.95 2.13 - 11.49 <0.001 
Upper GI cancer (n=75) 4.58 2.04 - 10.28 <0.001 
 
† Units of early RBC were entered into this model as an interaction term with Hb (g/L) at admission, 
hence the association of early RBC with odds of further bleeding is shown for the three different levels 
of Hb at admission.  
Pre-gastroscopy units of fresh frozen plasma, units of platelets, Rockall score, year of admission, and 
presence of chronic liver disease were also tested for association with further bleeding but were not 
significant (p>0.05) and not included in the final model.   The number of patients for each variable in 
the model are indicated if not already shown in Table 1. 
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Table 3.  Factors associated with 30-day mortality from first gastroscopy during last admission as 
estimated from a Cox survival model (n=2228 patients). 
 HR 95%CI p-value 
Rockall score    
<3 1.00 ref . 
3-4 3.58 1.58 - 8.11 0.002 
5-7 2.88 1.26 - 6.58 0.012 
≥8 7.74 3.28 - 18.25 <0.001 
    
Age at admission (years) 1.03 1.02 - 1.05 <0.001 
    
Morbidity indicators at admission     
No liver disease (n=2014) 1.00 ref . 
Child-Pugh Class A (n=65)† 2.14 0.89 - 5.17 0.090 
Child-Pugh Class B (n=90) 2.29 1.19 - 4.44 0.014 
Child-Pugh Class C (n=40) 1.95 0.64 - 5.97 0.241 
    
Malignant disease (n=58) 4.08 2.12 - 7.85 <0.001 
Anti-psychotic medication (n=73) 3.58 1.84 - 6.97 <0.001 
    
Procedural factors (Yes versus No)    
Gastroscopy > 25 minutes  (n=567) 2.08 1.38 - 3.13 <0.001 
Post-gastroscopy cardiac complications (n=24) 2.33 1.18 - 4.59 0.014 
Performed in ICU (n=78 2.83 1.08 - 7.42 0.035 
    
Coagulopathy at admission    
None 1.00 1.00 – 1.00 . 
INR>1.2 or Platelets<=150,000/mm3 1.93 1.19 - 3.11 0.007 
INR>1.5 or Platelets<=50,000/mm3 1.07 0.58 - 1.98 0.833 
    
Total RBC in admission    
None 1.00 1.00 – 1.00 . 
1 unit 0.61 0.18 - 2.10 0.436 
2 units 0.69 0.34 - 1.41 0.309 
3 units 0.74 0.32 - 1.69 0.474 
4 units 0.72 0.33 - 1.55 0.404 
5+ units 0.84 0.44 - 1.61 0.606 
    
Total FFP in admission    
None 1.00 1.00 – 1.00 . 
1-2 units 1.33 0.72 - 2.48 0.366 
3-4 units 1.61 0.64 - 4.01 0.310 
5+ units 2.77 1.30 - 5.91 0.008 
    
Total platelets in admission    
Serum albumin >=35 (n=1543)                   No platelets  1.00 ref . 
1 -2 unit platelets 1.74 0.61 - 4.95 0.296 
3+ units platelets 7.62 2.22 - 26.10 0.001 
    
Serum albumin <35 (n=817)                  No platelets  1.00 ref . 
1 -2 unit platelets 0.64 0.30 – 1.36 0.249 
3+ units platelets 1.50 0.63 – 3.60 0.363 
† Child-Pugh score could not be calculated for 19 patients with liver disease due to missing blood 
chemistry data and the HR for this group are not shown. 
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Table 4.  Factors associated with one-year mortality conditional upon surviving first 30 days since 
date of first gastroscopy in last UGIB admission (n=2120). 
 HR 95%CI p 
Rockall score    
<3 1.00 ref . 
3-4 1.65 1.07 - 2.55 0.023 
5-7 2.13 1.38 - 3.29 0.001 
≥8 2.68 1.54 - 4.67 <0.001 
    
Age at admission (years) 1.02 1.01 - 1.04 <0.001 
    
Morbidity indicators at admission  1.00 ref . 
No liver disease (n=1930) 1.00 1.00 - 1.00 . 
Child-Pugh Class A (n=59)† 3.25 1.78 - 5.93 <0.001 
Child-Pugh Class B (n=78) 2.48 1.46 - 4.21 0.001 
Child-Pugh Class C (n=36) 1.49 0.61 - 3.65 0.377 
    
Malignant disease (yes vs no) (n=41) 4.87 2.80 - 8.48 <0.001 
Anti-anaemic medication (yes vs no) (n=292) 1.60 1.25 - 2.03 <0.001 
Diuretic & potassium sparing medication (yes vs no) (n=405) 1.35 1.03 - 1.78 0.033 
Antibiotics (yes vs no) (n=81) 1.80 1.17 - 2.77 0.008 
    
Admission-related factors  1.00 ref . 
Length of hospital stay (^-0.5) 0.90 0.83 - 0.97 0.006 
Mallory-Weis tear cause of UGIB (n=145) 2.00 1.19 - 3.36 0.008 
    
Coagulopathy at admission     
On warfarin  (n=257)                                                    None 1.00 ref . 
INR>1.2 or Platelets<=150,000/mm3 0.28 0.02 - 3.17 0.304 
INR>1.5 or Platelets<=50,000/mm3 1.12 0.26 - 4.83 0.883 
    
Not on warfarin  (n=1863)                                             None   1.00 ref . 
INR>1.2 or Platelets<=150,000/mm3 1.42 1.01 - 2.00 0.046 
INR>1.5 or Platelets<=50,000/mm3 2.24 1.28 - 3.92 0.005 
    
Total RBC in admission    
None 1.00 ref . 
1 unit 1.01 0.55 - 1.86 0.975 
2 units 0.79 0.51 - 1.21 0.277 
3 units 0.82 0.47 - 1.42 0.471 
4 units 0.64 0.38 - 1.08 0.097 
5+ units 0.78 0.49 - 1.24 0.297 
    
Total FFP in admission    
None 1.00 ref . 
1-2 units 0.96 0.59 - 1.58 0.878 
3-4 units 1.11 0.52 - 2.35 0.791 
5+ units 2.57 1.33 - 4.96 0.005 
    
Total platelets in admission    
None 1.00 ref . 
1-2 unit platelets 0.72 0.42 - 1.26 0.252 
3+ units platelets 0.36 0.12 - 1.11 0.076 
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† Child-Pugh score could not be calculated for 17 patients with liver disease due to missing blood 
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